Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 7/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11995852 | 0.88 | EPHX1 (0.48) | CCR3MCHR1RAB9AMEN1POLB | |
| SCHEMBL1411686 | 0.88 | EPHX1 (0.48) | CCR3MCHR1RAB9AMEN1POLB | |
| SCHEMBL8989797 | 0.88 | CCR3 (0.43) | CCR3MCHR1RAB9AHTR2AMEN1 | |
| SCHEMBL13625896 | 0.88 | CCR3 (0.41) | CCR3MCHR1RAB9AHTR2AMEN1 | |
| SCHEMBL2392413 | 0.88 | EPHX1 (0.53) | CCR3MCHR1RAB9AKMT2AEPHX1 | |
| SCHEMBL13620001 | 0.87 | KMT2A (0.40) | CCR3MCHR1MEN1POLBKMT2A | |
| SCHEMBL2391511 | 0.87 | EPHX1 (0.55) | MCHR1RAB9AKMT2AEPHX1 | |
| SCHEMBL8988043 | 0.86 | MAPT (0.43) | CCR3MCHR1MEN1POLBKMT2A | |
| SCHEMBL1411818 | 0.86 | MAPT (0.41) | CCR3MCHR1CHRM4MEN1POLB | |
| SCHEMBL1411780 | 0.84 | KDM1A (0.41) | MCHR1HTR2APOLBKDM4EEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281322-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281322-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281322-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS | GOT1, GOT2, NDUFA7 | CCR3 2652/4885BTK 4001/4885PRMT3 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.